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Abstract
The core promoter (CP) of the viral genome plays an 
important role for hepatitis B virus (HBV) replication as 
it directs initiation of transcription for the synthesis of 
both the precore and pregenomic (pg) RNAs. The CP 
consists of the upper regulatory region and the basal 
core promoter (BCP). The CP overlaps with the 3’-end 
of the X open reading frames and the 5’-end of the pre-
core region, and contains cis -acting elements that can 
independently direct transcription of the precore mRNA 
and pgRNA. Its transcription regulation is under strict 
control of viral and cellular factors. Even though this 
regulatory region exhibits high sequence conservation, 
when variations appear, they may contribute to the 
persistence of HBV within the host, leading to chronic 
infection and cirrhosis, and eventually, hepatocellular 
carcinoma. Among CP sequence variations, those oc-
curring at BCP may dysregulate viral gene expression 
with emphasis in the hepatitis B e antigen, and con-
tribute to disease progression. In this review these mo-
lecular aspects and pathologic topics of core promoter 
are deeply evaluated.
© 2014 Baishideng Publishing Group Co., Limited. All rights 
reserved.
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Core tip: This review summarized the progress in our 
understanding of the core promoter of hepatitis B virus. 
This critical genomic region is involved in regulating 
hepatitis B virus (HBV) gene expression and viral rep-
lication, involving both host and virus-derived factors 
on its regulation. Such pivotal functions appear modi-
fied when genomic variations are detected and clinical 
implications are characterized. This review emphasizes 
several aspects of the HBV core promoter molecular 
biology and highlights its role on HBV life cycle. Finally, 
the most frequent genomic variations with their conse-
quent clinical correlations are described.
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INTRODUCTION
Hepatitis B virus (HBV) infection is a major cause of  
acute and chronic hepatitis, liver cirrhosis and hepatocel-
lular carcinoma worldwide. Nearly 350 million are chroni-
cally infected carriers and are at high risk of  complica-
tions from cirrhosis and primary liver cancer. Among 
these HBV carriers, 7%-30% are believed to be infected 
with HBV variants that express little or no hepatitis B e 
antigen (HBeAg)[1].
The HBV is an enveloped virus, containing a partially 
double-stranded DNA genome that is replicated via an 
RNA intermediate using its own encoded reverse tran-
scriptase (RT). The HBV RT does not have proofreading 
or editing activity, therefore, together with this enormous 
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daily virion production, errors inevitably occur during 
replication. The rate of  HBV virion production (up to 
1011 virions per day) is considerably higher than for hu-
man immunodeficiency virus (HIV) and hepatitis C virus, 
and approximately 10-fold higher than for other DNA vi-
ruses. The half-life of  HBV in plasma ranges from 1 to 3 
d whilst the half-life of  an infected hepatocyte is 10-100 
d. The error rate of  the HBV pol has been calculated as 
10-7 per nucleotide per day. Therefore, on a daily base, 
approximately 1014 nucleotides are replicated with poten-
tially 107 base pairing errors[2].
The major viral translational products include the 
precore and core, polymerase, large, medium and small 
envelope proteins and the X-protein as transcriptional 
regulator are encoded by four overlapping genes. The 
lifecycle of  HBV includes viral attachment and entry, vi-
ral uncoating in the cytoplasm and entry of  the partially 
double-stranded genome into the nucleus. In the nucleus 
the covalently closed circular DNA (cccDNA) is synthe-
sized in the form of  a viral minichromosome, creating 
a stable intermediate responsible for the persistence of  
the virus and rebound viraemia after withdrawal of  an-
tiviral therapy in some patients. The lack of  cccDNA in 
artificial host cells (e.g., hepatocytes of  HBV transgenic 
mice) suggests that host specific factors may regulate 
cccDNA formation. However, in a model of  hepatocyte 
nuclear factor 1α (HNF1α)-null HBV transgenic mice 
Raney et al[3] have reported that HBV cccDNA in the 
nucleus as well as its potential precursor protein-free re-
laxed circular HBV DNA in the cytoplasm were present 
in the hepatocytes, suggesting that cycling of  viral repli-
cation intermediates into the nucleus may occur in this in 
vivo model system.
The cccDNA is the template for transcription of  pre-
genomic (pg) RNA as well as subgenomic mRNAs, which 
are translated into the viral proteins in the cytoplasm. 
Encapsidation follows the binding of  the polymerase and 
core to the pgRNA in the cytoplasm. Synthesis of  the 
minus-strand DNA by reverse transcription and partial 
synthesis of  the plus-strand is accomplished by the HBV 
polymerase within the nucleocapsid. At this point the 
nucleocapsids are enveloped by budding into the endo-
plasmic reticulum followed by secretion from the cell or 
return to the nucleus to amplify the cccDNA reservoir in 
the nucleus[4].
The typical course of  hepatitis B infection involves 
an HBeAg-positive phase with high serum HBV DNA 
levels. Subsequently, patients undergo a process of  se-
roconversion in which HBeAg is lost and antibodies to 
HBeAg (anti-HBe) appear. Generally this signals the de-
cline of  HBV DNA to levels that are not detectable by 
unamplified assays and a return of  aminotransferase to 
normal values. Among some patients, for reasons that are 
not yet clear, the immune pressure associated with sero-
conversion selects for HBV variants that express little or 
no HBeAg. Although the patient may develop anti-HBe, 
active HBV DNA replication continues with associated 
liver damage[1,5].
The core promoter region regulates transcription of  
the pre-core region. Therefore certain mutations in this 
region can affect HBeAg synthesis without adversely af-
fecting the ability of  the HBV to replicate[6-9].
The primary aim of  this literature review is to de-
scribe the molecular biology, function and variants of  the 
hepatitis B virus core promoter.
HBV GENOMIC STRUCTURE AND 
ORGANIZATION
The HBV genome is a partly double stranded DNA 
composed of  a minus (-) and a plus (+) strand that has 
evolved structurally to a compact genetic organization 
(Figure 1). At the 5’-end of  the two strands, exhibits 
short cohesive end regions that contain two direct repeats 
(DRs) termed DR1 and DR2 that allow to maintain the 
circular configuration and are essential for viral replica-
tion[10]. The whole genome is carrying in the full-length 
coding (-) strand DNA (3.2 kb), while the incomplete 
non-coding (+) strand DNA region extends to around 
two-thirds of  the genome length with a variable 3’-end. 
The viral polymerase is covalently linked to the (-) strand 
DNA. This strand also contains on both, 5’- and 3’-ends, 
an 8-9-nucleotide-long terminal redundancy, termed “r” 
that is critical for the formation of  relaxed circular (rc) 
DNA synthesis. Once the viral (-) strand DNA synthesis 
is completed, a residual short RNA oligomer derived 
from the 5’-end pgRNA remains covalently bond to the 
5’-end of  the (-) strand DNA to serve as a template for 
(+) strand DNA synthesis. A small quantity (5%-10%) of  
double-stranded linear DNA can also be found packaged 
into the nucleocapsid instead of  rcDNA. During infec-
tion, both forms of  viral DNA (circular and linear) can 
be transformed to cccDNA in the hepatocyte nucleus. 
The HBV genome contains four overlapping open 
reading frames (ORFs) (P, preC/C, preS/S and X) en-
coded by the (-) strand with six start codons, four pro-
moters (preS1, preS2, core and X), and two enhancer 
elements (ENⅠ and ENⅡ) located upstream of  the core 
promoter. The viral genome also contains a common 3’
polyadenylation signal in the core gene and a number of  
cis -acting signals essential for DNA replication. 
Seven viral proteins (HBe; core; large, medium and 
small envelopes; polymerase; and HBx) are produced by 
translation of  the polyadenylated and capped viral RNA 
transcripts (3.5, 2.4, 2.1 and 0.7 kb). The open reading 
frame (ORF) P comprised four distinguishable domains 
that encode viral DNA polymerase (Pol, 90 kDa) exhibit-
ing multiple functions and involving the terminal protein, 
the spacer -that exhibits no enzymatic function-, the poly-
merase and reverse transcriptase activity -that catalyzes 
viral genomic synthesis-, and the fourth domain that en-
codes ribonuclease H[11]. The ORF preC/C partially over-
laps with ORF P and encodes the precore-core protein 
(HBeAg), the core protein (HBc), and the pgRNA. The 
pgRNA is initiated five nucleotides downstream from 
the precore initiation codon; it serves as a template for 
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the translation of  core protein (p21) and the viral DNA 
synthesis by reverse transcription within the nascent nu-
cleocapsids. The precore polypeptide (p25) is generated 
from the preC transcript, it is not packaged into viral nu-
cleocapsids instead it is proteolytic cleaved in both N and 
C termini when it moves to the secretory pathway to gen-
erate the mature secreted soluble HBeAg (p17)[11] (Figure 
2). The synthesis of  three integral envelope glycoproteins 
(large L, medium M and small S) is directed by the ORF 
preS/S, located within ORF P (between the spacer and 
the RT domains). The three glycoproteins contain HB-
sAg and they have distinct N-terminal domains because 
they use three in-frame AUG start codons[12]. The small-
est ORF X overlaps with ORF P. It encodes for the small 
protein HBx (17 kDa) which shares no homology with 
any known gene. This ORF is only found in all mamma-
lian hepadnaviruses and plays a central role in the patho-
genesis of  HBV-induced hepatocellular carcinoma[13,14].
REGULATION OF HBV DNA 
TRANSCRIPTION 
HBV promoters and enhancers
The HBV genome contains four promoters (core, preS1, 
preS2 and X) and two enhancers Ⅰ and Ⅱ (ENⅠ and 
ENⅡ) as cis-acting elements to control HBV transcrip-
tion of  the four 3.5, 2.4, 2.1 and 0.7 kb mRNAs, which 
have heterogeneous 5’-ends, with the exception of  preS1, 
which lacks a TATA box and produces transcripts with a 
defined 5’-end[15].
The transcription of  HBV mRNA can be modulated 
by both ENⅠ and ENⅡ[16]. ENⅠ(approximately 200 bp 
long) is the main stimulating element and up-regulates 
significantly preC and HBx mRNAs but has little effect 
on surface protein mRNAs. Its location partially overlaps 
the X promoter and exhibits binding sites for ubiquitous 
(NF1, AP1 and NFkB) and liver-specific [LRH-1/hB1F, 
HNF1, HNF3b, HNF4 and CCAAT/enhancer bind-
ing protein (C/EBP)] transcription factors[17,18]. ENⅠ
contains three distinct domains: a 5’ modulator element, 
a central core domain, and a 3’domain that overlaps with 
the HBx ORF. The central core domain contains the 
enhancer activity and binding sites for HNF3, RFX1, 
EFC, NF1, and a retinoic acid response element (RARE), 
which interacts with HNF4, the peroxisome proliferator-
activated receptor α-retinoid X receptor α (PPAR/RXR 
α) heterodimers and Chicken ovalbumin upstream pro-
moter transcription factors (COUP-TF). Interestingly, sig-
nal transducer and activator of  transcription-3 (STAT-3) 
factor may bind to NF1-and HNF3-binding sites and in-
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Figure 1  Genomic organization of hepatitis B virus. The inner circle depicts the rcDNA including the complete minus-strand DNA and the incomplete plus-strand 
DNA. The direct repeats, DR1 and DR2, as well as the two enhancers, ENⅠ and ENⅡ, are shown. The outer circle depicts the four viral RNAs, the core (C) or 
pgRNA, the pre-S (L) mRNA, the S mRNA, and the X mRNA. The common 3′-ends (poly-A) of the three mRNAs are indicated by the curve lines. The four protein-
coding regions are shown including the precore (PC) and core genes, the polymerase gene, and the X gene. The envelope genes pre-S1 (L), pre-S2 (M), and surface 
(S) overlap with the polymerase open reading frame.
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overlapping but genetically distinct core promoters that 
overlap the 3′ end of  the X ORF and the 5’ end of  the 
pre-C/C ORF and direct the transcription of  both preC 
and pregenomic RNAs[23].
The core promoter (CP, nt1575-1849) of  the viral 
genome has a pivotal role in the replication and mor-
phogenesis of  the virus[24] (Figure 3). It directs initiation 
of  transcription for the synthesis of  both the precore 
mRNA and pgRNA. The CP consists of  the BCP (nt 
1743-1849) and the upper regulatory region (URR, nt 
1613-1742), the latter containing both positive and nega-
tive regulatory elements that modulate promoter activ-
ity[25]. The BCP is sufficient for accurate initiation of  
both pre-C mRNA and pgRNA transcription in vivo. BCP 
contains major nuclear binding sites which is recognized 
by a variety of  the nuclear receptors super family, includ-
ing HNF4 and PPARα-RXRα heterodimer and a series 
of  transcription factors such as C/EBP to regulate the 
transcription both the pre-core RNA and the core RNA. 
Different biological functions of  pre-core and prege-
nomic RNA, as well as differential regulation of  BCP by 
these transcriptional factors may have profound effects 
on HBV replication and pathogenesis.
The BCP minimal essential sequence is a 108-bp frag-
ment (nts 1742-1849) that contains direct repeat 1 (DR1) 
which is required for reverse transcription[26]. It overlaps 
with the 3’-end of  the X ORF and the 5’-end of  the 
precore region, and contains cis-acting elements that can 
crease ENⅠfunction. Despite the 5’ modulator element 
and the 3’ domain have no enhancer activity, the former 
can interact with C/EBP and HNF1 transcription fac-
tors and increase the central core domain activity. ENⅡ 
is located upstream of  the core promoter and increases 
preferentially the transcription of  the preS1, preS2, and 
X promoters as well as the pg/pc mRNAs. ENⅡ con-
tains two regions, ⅡA and ⅡB, that act concomitantly 
as potent enhancer elements that bind various transcrip-
tion factors such as C/EBP, RXR, PPAR, HNF4, HNF3, 
FTF, hepatic leukemia factor and Sp1[19,20]. 
The preS1 and preS2 promoters control the envelope 
protein expression. The first one controls the transcrip-
tion of  the L mRNA (2.4 kb) while the preS2 promoter 
controls the transcription of  S and M mRNAs (2.1 kb), 
and it seems to be stronger than the preS1 promoter and 
leads to the production of  more S and M surface pro-
teins, which is necessary for virus secretion[21].
The transcription of  HBx is under the control of  its 
own promoter X to generate an approximately 0.7 kb-
long RNA. The X promoter has no TATA box, but its 
sequence is located upstream of  the transcription initia-
tion site and overlaps with the ENI 3’-end[13,22].
MOLECULAR BIOLOGY OF THE HBV 
CORE PROMOTER REGION
The 3.5 kb RNA synthesis is regulated by two partially 
 
   
           
 
5' 3'
Core promoter Precore Core
Precore mRNA
Precore protein (p25)
HBeAg (p17)
 Pregenomic RNA
 HBcAg (p21)
Figure 2  Transcription and translation of hepatitis B virus precore. The core promoter region regulates the transcription of precore mRNA and pregenomic RNA 
from the same open reading frame. The precore mRNA is translated into precore protein, which is processed at the N-terminal and C-terminal ends to HBeAg, a se-
cretory protein. Pregenomic RNA is reverse transcribed into HBV DNA and also translated into core protein (HBcAg), which overlaps with HBeAg.  HBcAg: Hepatitis B 
core protein antigen; HBeAg: Hepatitis B e antigen. 
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independently direct transcription of  the precore mRNA 
and pgRNA, both of  which are about 3.5 kb in length[27]. 
The URR comprises the negative regulatory element 
(NRE, nt 1613-1636) and the core upstream regulatory 
sequence (CURS, nt 1636-1742)[28]. The NRE, upstream 
of  ENⅡ, can repress both ENⅡ and CURS in differen-
tiated liver cells. It exhibits a minor inhibitory effect on 
its own but is strongly repressive in the presence of  EN
Ⅱ. At least three different subregions are distinguished: 
NRE-α, NRE-β and NRE-γ which suppress strongly the 
CP activity. NRE-γ also suppresses ENⅡ activity. The 
activity of  the NRE is cell-type dependent which could 
be ascribed to a differential regulation by cell type-depen-
dent protein factors[23,29].
The CURS acts as a regulatory region neither as a 
promoter nor with ENⅡ participation. It can be subdi-
vided into two domains: CURS-A (nts 1636-1703) and 
CURS-B (nts 1704-1743). The former can exert a posi-
tive regulatory effect on the BCP, although to a lesser 
degree than does the whole CURS. It can be subdivided 
in several sequence motifs, namely, α (nts 1646-1668) 
which is able to bind different transcription factors, γ (nts 
1671-1686) and δ (nts 1687-1703), which positively regu-
late BCP activity; in contrast, β (nts 1704-1714) regulates 
negatively[26].
The ENⅡ element regulates the activity of  the CP 
and partially overlaps the BCP and URR. Sequences lo-
cated directly at 5’ of  the BCP can positively regulate this 
promoter in a liver-specific manner through cis-acting ele-
ments in the CURS overlapping ENⅡ. Further upstream 
there are sequences that can negatively modulate the pro-
moter through the NRE. 
Sequences within the ENⅠ (nts 1074-1234) can also 
activate the BCP which is required for augmenting the 
CP extremely weak promoter activity. This whole region 
contains nucleotide motifs that constitute transcription 
factor binding sites, imparting at the same time liver cell 
specificity for optimal function of  these elements. This 
interaction between the cis-acting elements with ubiqui-
tous and liver-specific transcription factors is absolutely 
necessary for liver-specific expression from the CP. 
Moreover, the interaction between these trans-acting fac-
tors and the cis-acting elements allows the virus to coor-
dinately or differentially regulate the transcription of  the 
two mRNAs[27]. Moreover, the stimulation of  the BCP by 
ENⅡ and CURS can be repressed by the effect of  the 
upstream NRE[30]. 
The liver tropism of  HBV may involve different fac-
tors including the BCP and the enhancers as well as the 
interaction of  viral cis-acting elements with transacting 
factors present in various cell types and during differ-
ent stages of  liver cell differentiation[18]. The cooperative 
interaction of  different liver enriched and ubiquitous fac-
tors is necessary for liver-specific expression from the CP. 
1835
DR2
X ORF 1814
Core promoter
PreC-C ORF
HNF1
HNF3
HNF4
URR BCP
18491613
NRE CURS
DR1
A B
Figure 3  Molecular biology of the hepatitis B virus core promoter. The core promoter (CP) overlaps the 3’-end of the X open reading frame (ORF) and the 5’-end 
of the pre-C/C ORF. The CP comprises the upper regulatory region (URR) and the basic core promoter (BCP). The former involves a negative regulatory element (NRE) 
and a core upstream regulatory sequence (CURS) which can be further subdivided into two domains: CURS-A and CURS-B. The sequence of enhancer II and binding 
sites hepatocyte nuclear factor 1, 3 and 4 (HNF1, HNF3, HNF4) are shown. SPI: S promoter; DR: direct repeat. 
SPI  Enhancer Ⅱ
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Several transcriptional factors bind to regulatory sequence 
elements of  the CP such as C/EBP, HNF1, and HNF3. 
Multiple members of  the nuclear receptor superfamily 
of  transcription factors, including HNF4, RXR, PPAR, 
COUP-TF1 and apoAⅠ regulatory protein (ARP1), bind 
this regulatory element and differentially regulate synthe-
sis of  pre-C mRNA and pgRNA[19]. Their effects depend 
on their interactions: for example, binding of  HNF4 and 
TR2 may repress preC RNA synthesis, whereas PPAR α 
and RXR α can mediate its activation, and COUP-TF1 
can inhibit both preC and pgRNA synthesis. Human Sp1 
transcription factor increases the synthesis of  pgRNA by 
binding to three binding sites, but has no effect on the 
synthesis of  pre-C mRNA[21]. By binding to the AT-rich 
regions of  the CP the ubiquitous TBP plays an important 
role in the regulation of  transcription. Thus, the synthesis 
of  pre-C mRNA and pgRNA occurs from separate pro-
moters which are in turn, differentially regulated[28].
Selection of  the transcription initiation sites of  pre-C 
mRNA and pgRNA is not liver-cell specific and the URR 
is not required for the precise initiation of  either RNA 
type[21,31]. The 5’-ends of  pre-C mRNAs are more varied 
than are those of  pgRNA. The latter has been mapped to 
a single nt region: 1815 ± 5 whereas the 5’-ends of  pre-C 
mRNA map to nts 1785-1786 and 1791-1797. Such 
discrepancy could be ascribed to the presence of  three 
TATA-like boxes (AT-rich regions) within the BCP that 
are not canonical TATA box (TATAAA) and a fourth 
TATA-like box that controls the transcription of  pgRNA. 
The three AT-rich sequences: TA1, 5’-AGATTA-3’ (nts 
1750-1755); TA2, 5’-TTAAA-3’ (nts 1758-1762); and 
TA3, 5’-TATTA-3’ (nts 1771-1775); are located 20-35 bp 
5’ to the pre-C mRNA start sites and can bind recombi-
nant TATA-binding protein (TBP) as well as are required 
for the optimal transcription of  pre-C mRNA. TA4, 
5’-CATAAATT-3’ (nts 1788-1795), functions as both 
a TBP-binding site for initiation of  transcription 25-30 
bp downstream at the start site of  pgRNA, and as the 
initiator (Inr) sequence for some of  the pre-C mRNAs. 
The Inr is a minimal promoter element that overlaps the 
transcription start site. The 5’ boundary of  the pgRNA 
promoter is at nt 1788, the first nt of  its TATA box-like 
sequence. The pre-C Inr consists of  5’-CATA-3’ (nts 
1788-1791), overlaps the pre-C mRNA initiation sites 
and resembles the optimal Inr sequence: 5’-CA(T/G)T-3’. 
Using mutational studies it was shown that the 3’ bound-
ary of  this Inr element is at nt 1792. On the other hand, 
the pgRNA Inr element is the sequence 5’-CAACT-3’ (nt 
1817-1821) that overlaps the transcription initiation sites 
of  pgRNA and two of  its bases match the two most im-
portant bases of  the optimal Inr sequence. Therefore, the 
15-nt sequence (1788-1802) is sufficient to direct the ini-
tiation of  both pre-C and pgRNA because it contains the 
TATA-like element of  the pregenome promoter and the 
Inr of  the pre-C promoter. The transcription of  pre-C 
mRNA and pgRNA is regulated in a coordinate manner 
although the transcription of  the two mRNA species can 
be separated. Sequences in the URR can stimulate the ex-
pression of  both messages to a similar extent[28].
The pgRNA starts 3’ to the precore AUG and is 
translated into the core and polymerase proteins. As well, 
it serves as the template for the synthesis of  the negative 
DNA strand of  the virus by reverse transcription after 
encapsidation within the neosynthesized core particle[10]. 
The precore mRNA, which is slightly longer than the 
pgRNA and is initiated upstream of  the precore start 
codon, is the template for the translation of  the precore/
core protein that is post-translationally processed by pro-
teolysis to produce HBeAg, as previously described. 
BASAL CORE PROMOTER VARIANTS
Considering its pivotal role in viral replication, sequence 
variations within the CP in natural isolates is restricted. 
Nevertheless, several studies have focused on mutations 
within this region and, in particular, BCP because it may 
dysregulate viral gene expression and contribute to dis-
ease progression. In the CP, two highly conserved regions 
involved in the regulation of  transcription have been 
identified: nts 1770-1808 and nts 1813-1849. When muta-
tions in these regions occur, they are present in viral pop-
ulation with coexistence of  wild-type variants that must 
have a compensatory effect, overcoming the potentially 
lethal effect of  the mutation and allowing viral replication 
to proceed (Table 1). The pre-C mRNA initiation sites 
map within the first region[28,32] as does TA4 that controls 
pgRNA synthesis. Mutations within TA4 severely reduce 
the synthesis of  pgRNA, leaving synthesis of  the pre-C 
mRNAs unaffected[27,31]. In addition, this region has been 
shown to be essential for the trans-activating function of  
X protein[33]. The second conserved region contains the 
initiation site of  pgRNA transcription[28,32] as well as cod-
ing for the C-terminal of  the X protein. The overlap of  
this region with the 5’-end of  the pre-C ORF containing 
DR1 is a further reason for the low sequence divergence. 
Mutations in the CP region may have repercussions on 
viral gene expression and/or replication, with a concur-
rent impact on viral pathogenesis. 
The double mutation A1762T and G1764A in the 
BCP has been described in various disease states or set-
tings of  HBV infection[34-37]. The presence of  the double 
mutation is clearly associated with downregulation of  
HBeAg production, as demonstrated by transfection 
studies[7,9]. There is evidence to suggest that the double 
BCP mutation results in decreased levels of  the precore 
mRNA and therefore diminished production of  HBeAg. 
Taking into consideration that HBV BCP contains a 
binding site for nuclear receptors, the double mutation 
selectively abolishes the binding of  several nuclear recep-
tors without affecting that of  HNF4. It could stimulate 
the expression of  the precore RNA and the core RNA 
from the core promoter of  both the wild-type (WT) 
HBV and the double mutant, although its effect on the 
former was more prominent. The 1762/1764 double 
mutation also creates a binding site for the transcription 
factor HNF1 and changes two amino acids in the over-
lapping X protein sequence. HNF1, which did not affect 
the wild type BCP, suppressed the precore RNA expres-
Quarleri J. HBV core promoter
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sion of  the double mutant. Furthermore, the X protein 
did not affect the HNF4 activity on the core promoter 
and affected the HNF1 activity on the core promoter of  
only the double mutant[38] (Table 1).
During in vivo infection its increased presence could 
be temporally correlated with HBe seroconversion often 
preceding HBeAg clearance by many years[39] but still 
there are discrepant results on its relationships with the 
HBeAg negativity considering that some of  the stud-
ies were performed at different stages of  chronic liver 
disease. More recently its presence was also related with 
higher viral load levels[40] in opposite with other previous 
findings[7,41]. These discrepancies could be associated with 
the upregulation of  pgRNA production, promoting en-
capsidation and core protein production[42] whereas oth-
ers, however, reported decreased precore mRNA levels, 
but wild-type levels of  replication and gene expression[42]. 
Such differences observed in transcript levels when 
BCP mutations are detected could be explained by the 
alteration of  a nuclear receptor binding site for HNF1 
that appears to be essential for this activity. By using the 
woodchuck animal model and the woodchuck hepatitis 
virus (WHV), such variations in the HNF1 binding site 
diminished significantly the synthesis of  viral pgRNA[43]. 
The BCP double mutation is correlated with the 
L130M and V131I mutations in the overlapping X ORF 
gene product. The removal of  the nuclear receptor 
binding site had no effect on the transcription of  HBV 
mRNAs as was shown by transfection studies in Huh7 
hepatoma cells, the two codon change in the X protein 
suppressed both transcripts, and the creation of  the 
HNF1 site restored the pgRNA level[44]. In addition, be-
tween both, the T1762 change is decisive for the mutant 
phenotype as was revealed by analysis of  revertants with 
either one or the other of  the BCP mutations[7]. Studies 
from chronically infected patients have provided further 
information regarding the double A1762T/G1764A 
mutation in relation to genotype[45,46]. Compared with 
genotype A and B cases, patients with genotypes C and 
D have lower rates and usually delayed onset of  sponta-
neous HBeAg seroconversion. HBV-genotype C has a 
higher frequency of  A1762T/G1764A mutation and preS 
deletion, and a higher viral load than genotype B. Similar-
ly, genotype D has a higher prevalence of  BCP A1762T/
G1764A mutation than genotype A[47]. The A1762T/
G1764A BCP mutations in genotype C isolates correlated 
with increased replication capacity, while the A1752G/T 
mutation found in genotype B isolates correlated with 
low replication capacity[48]. Interestingly, genotype C iso-
lates with wild-type BCP sequences replicated less effi-
ciently than genotype B isolates, due to less efficient tran-
scription of  the pgRNA, but more efficient virion release 
was observed with the former[49]. Core promoter changes 
are significantly more common in patients infected with 
HBV genotypes exhibiting C at nucleotide 1858, while 
precore stop codon changes appears exclusively in those 
genotypes that have T at nucleotide 1858. Nevertheless, 
the double BCP and the precore stop codon mutations 
are far from being mutually exclusive[50]. Among HBV 
genotype C infected patients from China, those acutely 
infected with BCP/precore mutant viruses had higher 
viral load than chronic patients with the mutant virus but 
both showed a lower prevalence of  A1762T/G1764A, 
G1896A, and G1899A, but higher prevalence of  T1758C 
mutations. The T1758C and A1762T/G1764A mutations 
appeared as mutually exclusive[51].
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  Nucleotide position Clinical relevance
  1762T + 1764A 
  (BCP double mutant)
Chronic HBV 
Fulminant hepatitis 
Decrease in HBeAg production and increase viral replication
Diminished binding of a liver-specific transcription factor, resulting in a decrease in HBeAg, but unchanged amounts of HBV 
pregenomic RNA
Enhance viral replication through the combined effects of X gene mutations and the appearance of a HNF-1 transcription factor 
binding site 
Elevated ALT (diminishing circulating HBeAg levels → augment the host immune response to HBV-infected hepatocytes → 
increasing hepatocyte apoptosis) 
More often in patients with HBV genotypes that have 1858C (i.e., genotype C)
  1762T HBeAg seroconversion and histological inflammation 
  1764A No suppression on HBV RNA transcription and only slightly decreases the efficiency of virus replication
  1653T Usually together with the 1762T + 1764A in patients with fulminant hepatitis and hepatocellular carcinoma 
  1753-1757 Together with the 1762T + 1764A mutation, have been detected in patients with fulminant hepatitis and in patients with HCC
ALT levels and histological changes 
  1764A/T + 1766A/G Found in active and inactive disease in conjunction with 1810T + 1811T double mutation 
1762A1766A mutation, together with 1762T, was found in fulminant hepatitis and HCC patients 
The 1764T + 1766G mutation was found in a patient with fulminant recurrent hepatitis after liver transplantation, but was absent 
in patients with fulminant hepatitis.
  1766T + 1768A Fulminant hepatitis 
Together with 1762T + 1764A, in a patient with recurrent hepatitis following liver transplantation 
With 1764A in a HBeAg-negative asymptomatic carrier
Exacerbation of HBV infection and created two overlapping low-affinity HNF1 sites
Table 1  More frequent basal core promoter mutations and their clinical relevance
BCP: Basal core promoter; HBV: Hepatitis B virus; HNF-1: Hepatocyte nuclear factor 1; ALT: Alanine transaminase; HCC: Hepatocellular carcinoma.
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The double mutation has been detected with in-
creased frequency in patients with fulminant hepatitis, 
including children, those with HBeAg- and anti-HBe-
positive chronic hepatitis, and HCC patients, but less fre-
quently in asymptomatic chronic carriers. In addition, it 
has been detected in immunosuppressed, liver transplant, 
and seronegative patients. Interestingly, it was recently 
reported that BCP T1762/A1764 mutant is an indepen-
dent risk factor for progression to cirrhosis rather than 
hepatocellular carcinoma (HCC) in chronic HBV infec-
tion[52]. There are differences in the prevalence of  such 
variants between studies in various settings, and this may 
relate to differences between prevalent genotypes, the im-
portance of  which is not always recognized and therefore 
not clearly reported[53-56]. Very recently Yang et al[57] have 
postulated that a quantitative analysis of  the BCP double 
mutation (and G1896A) can predict interferon-induced 
HBeAg seroconversion.
The BCP mutations, as mentioned here, have been 
found in patients regardless of  HBeAg status. However, 
in anti-HBe-positive patients, the double mutation was 
often accompanied by T1753C/G mutation. In addi-
tion, other point mutations upstream and downstream 
of  T1762/A1764 have been described, occurring either 
alone or in combination with the double mutation, and in 
different settings, including chronic hepatitis, fulminant 
hepatitis B, HCC, and liver transplantation[46,58,59]. More 
recent studies have identified additional mutations in 
the BCP region that are prevalent in HCC patients, and 
particularly novel individual and combination patterns of  
mutations in the X/precore region of  HBV genotype D1 
as predictors of  HCC[46]. These include T1673/G1679, 
G1727, C1741, C1761, A1757/T1764/G1766, T1773, 
T1773/G1775 and C1909 (Table 1). 
The mutations G1613A (NRE) and C1653T, both 
of  which tended to also occur simultaneously in HCC 
patients may suppress HBeAg production, enhanced viral 
DNA synthesis, and bound RFX1 with higher affinity. 
Since the 1762/1764 mutations overlap with the X ORF 
and lead to amino acid changes in the X protein (L130M 
and V131I, respectively), this double substitution on its 
own or together with G1386A (V5M) was encountered 
at a significant rate in HCC patients by activating NF-
kB activity[60]. Synergistic effects of  A1896, C1653T and 
T1762/A1764 mutations in genotype C2 on development 
of  hepatocellular carcinoma has been reported[61]. Thus, 
to summarize, T1653, V1753, T1762, A1764, T1766, 
and A1768 have been found to occur more frequently in 
HCC patients[62]. 
The double BCP mutation was found to be associ-
ated with increased risk of  HCC independent of  geno-
type, while the precore A1896 mutation was associated 
with decreased risk. According the the Risk Evaluation 
of  Viral Load Elevation and Associated Liver Disease/
Cancer-Hepatitis B Virus study, the infection by geno-
type B strains exhibiting the BCP double mutation over 
a 10-year period increases 23% the risk of  developing 
HCC. Likewise, the presence of  family history of  HCC 
multiplies the risk of  HCC at each stage of  HBV infec-
tion[63-64].
OTHER CORE PROMOTER VARIANTS
Core promoter mutations other than those at positions 
1762 and 1764 can have major impact on viral DNA 
replication and HBeAg expression[34]. In vitro studies re-
veal that CP mutants with additional mutations (T1753C 
and/or C1766T) replicated at high level (Table 1). When 
mutational complexes were assayed, the 1762/1764/1766 
and 1753/1762/1764/1766 showed higher replication 
rates and lower HBeAg expression than 1762/1764 mu-
tations alone, whereas the 1753/1762/1764 variant was 
not much different from the double BCP mutant. Single 
mutations including T1753C/A/G (V), 1762/1764, 
A1846T, G1896A, 1899 and A/G1913, as well as triple 
mutations 1753/1762/1764 and 1762/1764/1766 or 
T1768A, were more frequently detected in patients with 
acute-on-chronic liver failure than in patients with chron-
ic hepatitis, and mostly associated with genotype B- than 
C-infected patients[65]. 
Deletions within the CP region -mostly at BCP- and 
varying in length from 1 to 21 bp have been reported 
once again in different settings. These include fulminant 
hepatitis, chronic hepatitis, asymptomatic infection, sero-
logically silent infection, HCC, renal dialysis with atypical 
HBsAg-negative infections characterized by either the 
presence of  viral antibodies alone or no serological mark-
ers, and liver and renal transplantation, HIV coinfec-
tion[66]; they are also found in patients who have survived 
hematological malignancies or solid tumors[28,67]. Such 
deletion variants are often characterized by low viremia 
levels, and may need help from the wild-type virus for 
survival[68]. Likewise, reduced levels of  transcription and 
progeny virus production were obtained by transfec-
tion with clones having an 8 bp deletion in the BCP (nt 
1768-1775)[69]. It appears, therefore, that the strain genetic 
background in which the BCP and G1896A mutations 
arise, in relation to additional ones, determine replica-
tion rate, expression of  HBeAg, and pathogenicity[23]. A 
limited number of  reports have shown the presence of  
deletions in the URR[70,71] or in the region of  the CP over-
lapping the pre-C ORF[72]. 
Insertions within the BCP have been described in 
patients with CH[73] and in those undergoing orthotopic 
liver transplantation[74]. One patient who had a fulminant 
exacerbation of  CH after heart transplantation was re-
ported to be infected with a high-replicating HBV variant 
carrying an 11-bp insertion in the CP[75]. This insertion 
occurred shortly before, or during, FH and created a 
binding site for HNF1. Thus, the emergence or presence 
of  a novel HNF1, or putative HNF3, site may be related 
to fulminant exacerbating hepatitis in immunosuppressed 
patients. This concurs with the presence of  such strains 
in renal transplant patients with severe liver disease but 
not in those with mild disease[28,71]. Simultaneous detec-
tion of  deletion and insertion at BCP was recently re-
ported in a single patient with HCC from South Africa 
with concomitant presence of  other variations that could 
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accelerate the HCC development[76]. 
The G1862T substitution affecting codon 17 of  
the precore protein of  the virus was only observed in 
patients infected with genotype B. This variant was five 
times more common in patients with fulminant hepatitis 
than in chronic carriers. The G1862T mutation leads to 
substitution of  valine for phenylalanine, affecting the - 3 
position in the signal peptidase recognition motif, im-
pairing the processing of  the precore/core protein into 
HBeAg[77]. A similar behavior was described for viral vari-
ants carrying the C1856T mutation. It leads to P15S sub-
stitution at precore. This amino acid change affects the 
signal peptide also, and may therefore affect production 
of  HBeAg from the precursor precore/core, but there 
are no experimental data supporting this proposition at 
the moment[23]. This variant was initially found by chance 
while sequencing the complete HBV genome of  an HIV 
positive patient with a strange serological profile[78], and then 
in Hong Kong Chinese patients with chronic hepatitis[79].
HBV possesses the smallest genome of  any virus 
known to infect man. Therefore, it is not surprising that 
HBV utilizes its genetic material economically. The core 
promoter is an emblematic model of  this strategy whose 
DNA harbors several pivotal functions. Its sequence in-
volves three critical elements (ENⅡ, BCP, and the over-
lapping X ORF) which are able to execute critical viral 
functions (stimulate the S, X, and CP; regulate the tran-
scription of  both pre-C mRNA and pgRNA; encode the 
X protein with trans-activating functions, respectively). 
Its integrity appears essential to maintain viral replication, 
and variation may contribute to the persistence of  HBV 
within the host, leading to chronic infection and, eventu-
ally, cellular transformation.
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